307 related articles for article (PubMed ID: 28666778)
1. PSMA ligands in prostate cancer - Probe optimization and theranostic applications.
Lütje S; Slavik R; Fendler W; Herrmann K; Eiber M
Methods; 2017 Nov; 130():42-50. PubMed ID: 28666778
[TBL] [Abstract][Full Text] [Related]
2. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
3. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific membrane antigen theranostics: therapy with lutetium-177.
Ferdinandus J; Violet J; Sandhu S; Hofman MS
Curr Opin Urol; 2018 Mar; 28(2):197-204. PubMed ID: 29278583
[TBL] [Abstract][Full Text] [Related]
6. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
7. Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer.
Lee BS; Kim MH; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim HS; Kim MH; Kil HS; Han SJ; Lee YJ; Lee KC; Lim SM; Chi DY
Mol Cancer Ther; 2021 Dec; 20(12):2410-2419. PubMed ID: 34725194
[TBL] [Abstract][Full Text] [Related]
8. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
Ilhan H; la Fougère C; Krause BJ
Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
[TBL] [Abstract][Full Text] [Related]
9. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
10. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
11. Validation of a [Al
Al-Momani E; Israel I; Samnick S
Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
[TBL] [Abstract][Full Text] [Related]
12. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
13. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
14. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
15. Local Salvage Treatment of Post-brachytherapy Recurrent Prostate Cancer via Theranostic Application of PSMA-labeled Lutetium-177.
Demirkol MO; Kiremit MC; Acar O; Falay O; Ucar B; Esen T
Clin Genitourin Cancer; 2018 Apr; 16(2):99-102. PubMed ID: 29074285
[No Abstract] [Full Text] [Related]
16. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
[TBL] [Abstract][Full Text] [Related]
18. The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation.
Miyahira AK; Soule HR
J Nucl Med; 2022 Mar; 63(3):331-338. PubMed ID: 34675109
[TBL] [Abstract][Full Text] [Related]
19. New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177).
Zha Z; Choi SR; Li L; Zhao R; Ploessl K; Yao X; Alexoff D; Zhu L; Kung HF
J Med Chem; 2022 Oct; 65(19):13001-13012. PubMed ID: 36103652
[TBL] [Abstract][Full Text] [Related]
20. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
Plichta KA; Graves SA; Buatti JM
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]